Every material Form 8-K Innoviva filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Innoviva reported third-quarter 2026 results with total revenue of $106.1 million, down 1.6% from $107.8 million a year earlier, while U.S. net product sales rose 45% to $43.3 million. The company swung to a net loss of $73.9 million, or $1.03 per basic share, mainly because of unfavorable fair value changes in its equity and long-term investments, and it reaffirmed its 2026 guidance of at least $150 million in U.S. net product sales.
Total revenue was $106.1 million versus $107.8 million in Q3 2025; gross royalty revenue from GSK was stable at $58.1 million.
Net loss of $73.9 million, or $1.03 per basic share, compared with net income of $89.9 million in Q3 2025, driven by a $139.5 million net unfavorable fair value change in equity and long-term investments.
Income from operations rose 21.9% to $42.2 million, and cash and cash equivalents totaled $581.4 million as of September 30, 2026.
During Q3 2026 the company repurchased 1,226,948 shares for $26.3 million under its $125 million buyback program.
Innoviva reported second-quarter 2026 results for the period ended June 30, 2026. Total revenue grew 19% from a year earlier, led by 46% growth in net product sales, but the company posted a net loss of $83.4 million, or $1.14 per basic share, compared with net income of $63.7 million a year earlier. The loss was driven mainly by unfavorable changes in the fair value of its equity and long-term investments, primarily from a lower share price of Armata Pharmaceuticals.
Total revenue was $119.6 million, up from $100.3 million in the second quarter of 2025.
Net product sales were $51.8 million, up 46%, with U.S. sales of $36.6 million.
Net loss was $83.4 million, or $1.14 per basic share, versus net income of $63.7 million in the prior-year quarter.
The company repurchased 1,403,247 shares for $31.4 million in the quarter under its $125 million program.
Innoviva directors Derek Small and Mark DiPaolo resigned on May 12, 2026, to focus on Syndeio BioSciences, where Small is CEO and DiPaolo is expected to take an executive role. On May 18, 2026, the board elected Josephine Linden as a director, and she is expected to serve on the Audit Committee. The filing describes the resignations as unrelated to any disagreement with the company, and the change is a board composition update rather than a financial result.
Derek Small and Mark DiPaolo resigned from the board on May 12, 2026, to focus on Syndeio BioSciences Inc.
Josephine Linden was elected to the board on May 18, 2026; the board has determined she is independent.
Linden is expected to serve on the Audit Committee and will receive a $125,000 initial RSU award plus prorated annual awards of $206,250 in RSUs and options on 9,166 shares.
Innoviva reported first-quarter 2026 total revenue of $98.0 million, up 11% from $88.6 million a year earlier, and net income of $186.6 million, or $2.52 per basic share, compared with a net loss of $46.6 million in the first quarter of 2025. The swing to profit was driven mainly by $191.2 million in net favorable fair value changes on investments, primarily Armata Pharmaceuticals, while income from operations fell to $38.2 million from $41.4 million.
Total revenue of $98.0 million, up 11% from $88.6 million in Q1 2025; net product sales rose 37% to $41.4 million.
Net income of $186.6 million ($2.52 basic EPS) versus a net loss of $46.6 million ($0.74 loss per share) in Q1 2025, driven mainly by $191.2 million in net favorable fair value changes, primarily Armata Pharmaceuticals.
Income from operations was $38.2 million, down from $41.4 million a year earlier.
Cash and cash equivalents totaled $603.1 million at March 31, 2026; the company repurchased 971,066 shares for $20.4 million in the quarter under its $125 million program.
Innoviva reported fourth-quarter and full-year 2025 results. Total revenue rose 25% in the quarter to $114.6 million and 15% for the year to $411.3 million, and net income rose sharply, helped mainly by fair value gains on its Armata Pharmaceuticals investments. Operating income fell slightly in both periods, and the company also disclosed a $125 million share repurchase program.
Q4 2025 total revenue was $114.6 million, up from $91.8 million in Q4 2024; full-year revenue was $411.3 million, up from $358.7 million.
Q4 2025 net income was $164.2 million ($2.19 basic per share), compared with $20.3 million in Q4 2024; full-year net income was $271.2 million.
Q4 2025 income from operations was $39.0 million, down from $43.1 million a year earlier, and gross royalty revenue from GSK fell to $58.4 million from $66.0 million.
Cash and cash equivalents were $550.9 million at December 31, 2025, and the company initiated a $125 million share repurchase program in the fourth quarter.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Innoviva filing is on SEC EDGAR ↗. 8-K briefs of other companies →